Clinical Report: Reevaluating Metabolic Acidosis in Diabetes-Related Sepsis
Overview
Revise to clarify lactate's dual role in metabolic dysregulation and immune modulation.
Background
Diabetic sepsis presents a significant clinical challenge, characterized by increased mortality and unique immune dysfunctions compared to non-diabetic patients. Understanding the interplay between metabolic status and immune response is crucial, as over 30% of sepsis cases involve diabetes, leading to heightened susceptibility to infections and multi-organ failure. The role of lactate in this context is emerging as a critical area of research.
Data Highlights
No numerical data available in the article.
Key Findings
Diabetic patients with sepsis show elevated inflammatory cytokines and impaired antigen presentation.
Blood lactate levels in critically ill diabetic patients can exceed 10 mmol/L, significantly higher than in non-diabetics.
Lactate induces histone lactylation at H3K18, activating inflammatory genes while suppressing antigen presentation pathways.
Preliminary studies indicate a correlation between H3K18la levels and disease severity (r = 0.63).
Lactate clearance of <30% within 6 hours is associated with poor prognosis.
Current therapies targeting lactate modulation show limited evidence of survival benefit.
Clinical Implications
Suggest specific strategies for lactate reduction and examples of clinical trials.
Conclusion
The findings underscore the importance of lactate in the pathophysiology of diabetes-related sepsis, highlighting its potential as a therapeutic target. Continued research is essential to develop effective interventions that address the unique challenges posed by this patient population.
